Compare Payoneer Global Inc (PAYO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs TransMedics Group Inc — how do they compare? Payoneer Global Inc trades at $7.11 (market cap $2.42B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and Payoneer Global Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| PAYO | TMDX | |
|---|---|---|
Market Cap | $2.42B | $3.06B |
Sector | Technology | Technology |
52-Week High | $7.18 | $150.42 |
52-Week Low | $4.27 | $61.99 |
Enterprise Value | $2.16B | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.13, down 0.56% on the day, with a market cap of approximately $2.3 billion. The stock shows mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, revenue grew to $821 million in 2025 with a 79.4% gross margin, though net income margin declined to 5.83%. Recent news highlights the pending acquisition by Nuvei for $7.40 per share, with multiple law firms investigating the fairness of the deal price.
The acquisition offer at $7.40 provides near-term upside potential, but investor sentiment is cautious due to legal scrutiny. Long-term growth prospects remain positive with expanding global operations, though earnings volatility and competitive pressures present risks. Analyst consensus is bullish with 60% buy ratings, but the stock faces execution risks in integrating the India tech hub and maintaining B2B growth momentum.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
